ArticlePacific Symposium on Biocomputing. Pacific Symposium on Biocomputing2013
Spectral clustering strategies for heterogeneous disease expression data.
Article in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- MOUSSE: Multi-Omics Using Subject-Specific SignaturEs.Cancers · 2021Article
- Article
- Identifying Windows of Susceptibility by Temporal Gene Analysis.Scientific reports · 2019Article
- T-ReCS: stable selection of dynamically formed groups of features with application to prediction of clinical outcomes.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2015Article
- MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603.Clinical epigenetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Clustering of gene expression data simplifies subsequent data analyses and forms the basis of numerous approaches for biomarker identification, prediction of clinical outcome, and personalized therapeutic strategies. The most popular clustering methods such as K-means and hierarchical clustering are intuitive and easy to use, but they require arbitrary choices on their various parameters (number of clusters for K-means, and a threshold to cut the tree for hierarchical clustering). Human disease gene expression data are in general more difficult to cluster efficiently due to background (genotype) heterogeneity, disease stage and progression differences and disease subtyping; all of which cause gene expression datasets to be more heterogeneous. Spectral clustering has been recently introduced in many fields as a promising alternative to standard clustering methods. The idea is that pairwise comparisons can help reveal global features through the eigen techniques. In this paper, we developed a new recursive K-means spectral clustering method (ReKS) for disease gene expression data. We benchmarked ReKS on three large-scale cancer datasets and we compared it to different clustering methods with respect to execution time, background models and external biological knowledge. We found ReKS to be superior to the hierarchical methods and equally good to K-means, but much faster than them and without the requirement for a priori knowledge of K. Overall, ReKS offers an attractive alternative for efficient clustering of human disease data.
Indexed as
Identifiers
23424126PMC4449339What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.